Do you know an oncology nurse that has exhibited outstanding care and compassion who deserves to be honored as our 2020 Extraordinary Healer? Tell us about him or her! Each year, CURE® magazine gives readers a unique opportunity to honor an oncology nurse through the Extraordinary Healer® Award for Oncology Nursing by describing the compassion, expertise and helpfulness that a special…
Pamela J Sung, MD, PhD, details differentiation therapy in acute myeloid leukemia, focusing on newer targets and preclinical evidence for a novel FLT3 combination.
Tazemetostat plus pembrolizumab was tolerable in platinum-exposed or -ineligible advanced urothelial carcinoma.
Natural killer cells hold promise for treating cancer; Yale researchers have found a way to overcome their main limitation.
The FDA has granted fast track designation to CT-0525 for the treatment of patients with HER2-overexpressing solid tumors.
Ciara Kelly, MBBCh, BAO, discusses ongoing GIST research for GIST Awareness Day.
A 3 year survival update on the RELATIVITY-047 trial (NCT03470922), a global, randomized, double-blind phase 2/3 study comparing nivolumab plus relatlimab vs nivolumab in previously…
An economic analysis of Zanubrutinib versus Acalabrutinib and associated QoL benefits in AE management in patients with B-cell malignancies.
Michelle Mendoza, PhD, and Jeffrey Weiss, PhD, received a $2.6 million grant from the NIH to research how tension in lung tissue affects the growth…
Jonathan W. Riess, MD, MS, and James Chih-Hsin Yang MD, PhD, debate the benefits of upfront osimertinib with/without chemotherapy in EGFR-mutant NSCLC.
To bring key stakeholders (HCPs, pharmaceutical and biotech companies, associations, and advocacy groups) together for the common purpose of providing accurate and relevant information to…
